Skip to main content
. 2021 Nov 2;13(12):e15098. doi: 10.15252/emmm.202115098

Figure 3. CSF p‐tau235 assay across Alzheimer’s disease continuum (TRIAD cohort).

Figure 3

  1. Box‐and‐whiskers plot showing CSF p‐tau235 concentrations in the different groups: amyloid‐negative cognitively unimpaired (CU−) participants (n = 50), participants across Alzheimer’s disease (AD) continuum (amyloid‐positive cognitively unimpaired (CU+, n = 32); amyloid‐positive mild cognitive impairment (MCI+, n = 20); AD (n = 20) and non‐AD cases (n = 19)). CSF p‐tau235 is highly specific for AD pathology. Cut‐off value for CSF p‐tau235 positivity is displayed with black dashed line (19.92 pg/ml).
  2. ROC analysis showing the high diagnostic accuracy of CSF p‐tau235 discriminating AD from CU−, CU+, MCI+ and non‐AD groups.
  3. ROC analysis comparing AUC values of CSF p‐tau235, p‐tau231 and p‐tau217 discriminating CU+ from CU−. CSF p‐tau235 discriminating accuracy was statistically lower than that of CSF p‐tau231, but not CSF p‐tau217.
  4. ROC analysis comparing AUC values of CSF p‐tau235, p‐tau231 and p‐tau217 discriminating amyloid‐negative cognitively impaired (CI−, non‐AD) from amyloid positive cognitively impaired (CI+, MCI+ and AD). CSF p‐tau235 performance was statistically similar to that of CSF p‐tau217 and p‐tau231.

Data information: Box‐and‐whisker plots show the median and the 25th and 75th percentiles. P‐values determined using one‐way ANOVA adjusted by age and sex followed by Bonferroni‐corrected post‐hoc comparison (*P < 0.05, ****P < 0.0001). CSF p‐tau235 cut‐off was determined as mean ± 2 SD of the A−T− group in ALFA+ cohort (19.92 pg/ml). ROC analysis (B–D) indicating the diagnostic accuracy of the studied biomarkers as AUC values. The DeLong test (C, D) was used to determine statistical differences between biomarker performances (P < 0.05 is indicated in bold). All samples were run in singlicates.